Wai Yuen Tong Medicine Holdings Limited (0897.HK)
HKD 0.36
(-1.37%)
HKD 0.36
(-1.37%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -15.35 Million HKD | 25.15% |
| 2022 | -20.51 Million HKD | 81.16% |
| 2021 | -108.91 Million HKD | 71.03% |
| 2020 | -375.99 Million HKD | -185.74% |
| 2019 | 438.54 Million HKD | 487.65% |
| 2018 | 74.62 Million HKD | 164.57% |
| 2017 | -115.58 Million HKD | -23.88% |
| 2016 | -93.3 Million HKD | -467.52% |
| 2015 | 25.38 Million HKD | -79.02% |
| 2014 | 120.97 Million HKD | -25.95% |
| 2013 | 163.37 Million HKD | 10.07% |
| 2012 | 148.43 Million HKD | 165.41% |
| 2011 | -226.92 Million HKD | -328.91% |
| 2010 | 99.13 Million HKD | 116.46% |
| 2009 | 45.79 Million HKD | 113.24% |
| 2008 | -345.9 Million HKD | -514.84% |
| 2007 | 83.38 Million HKD | 740.29% |
| 2006 | 9.92 Million HKD | 109.35% |
| 2005 | -106.15 Million HKD | -57.9% |
| 2004 | -67.22 Million HKD | -124.19% |
| 2003 | -29.98 Million HKD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q2 | 3.54 Million HKD | 0.0% |
| 2023 FY | -15.35 Million HKD | 25.15% |
| 2023 Q4 | -18.9 Million HKD | 0.0% |
| 2022 Q2 | -53.38 Million HKD | 0.0% |
| 2022 FY | -20.51 Million HKD | 81.16% |
| 2022 Q4 | 32.86 Million HKD | 0.0% |
| 2021 Q4 | -123.02 Million HKD | 0.0% |
| 2021 FY | -108.91 Million HKD | 71.03% |
| 2021 Q2 | 14.1 Million HKD | 0.0% |
| 2020 Q4 | -142.8 Million HKD | 0.0% |
| 2020 Q2 | -233.19 Million HKD | 0.0% |
| 2020 FY | -375.99 Million HKD | -185.74% |
| 2019 FY | 438.54 Million HKD | 487.65% |
| 2019 Q4 | 63.61 Million HKD | 0.0% |
| 2019 Q2 | 32.21 Million HKD | 0.0% |
| 2018 FY | 74.62 Million HKD | 164.57% |
| 2018 Q4 | 34.24 Million HKD | 0.0% |
| 2018 Q2 | 40.38 Million HKD | 0.0% |
| 2017 Q2 | -40.49 Million HKD | 0.0% |
| 2017 Q4 | -75.08 Million HKD | 0.0% |
| 2017 FY | -115.58 Million HKD | -23.88% |
| 2016 Q4 | -55.03 Million HKD | 0.0% |
| 2016 Q2 | -38.26 Million HKD | 0.0% |
| 2016 FY | -93.3 Million HKD | -467.52% |
| 2015 Q2 | 67.65 Million HKD | 0.0% |
| 2015 Q4 | -42.26 Million HKD | 0.0% |
| 2015 FY | 25.38 Million HKD | -79.02% |
| 2014 Q2 | 11.49 Million HKD | -71.87% |
| 2014 FY | 120.97 Million HKD | -25.95% |
| 2014 Q3 | 30.24 Million HKD | 163.23% |
| 2014 Q4 | 30.24 Million HKD | 0.0% |
| 2014 Q1 | 40.84 Million HKD | 0.0% |
| 2013 FY | 163.37 Million HKD | 10.07% |
| 2013 Q4 | 40.84 Million HKD | 0.0% |
| 2013 Q3 | 40.84 Million HKD | -31.91% |
| 2013 Q2 | 59.98 Million HKD | 61.64% |
| 2013 Q1 | 37.1 Million HKD | 0.0% |
| 2012 Q1 | -56.73 Million HKD | 0.0% |
| 2012 Q2 | -56.73 Million HKD | 0.0% |
| 2012 Q3 | 37.1 Million HKD | 165.41% |
| 2012 Q4 | 37.1 Million HKD | 0.0% |
| 2012 FY | 148.43 Million HKD | 165.41% |
| 2011 Q1 | 24.78 Million HKD | 0.0% |
| 2011 FY | -226.92 Million HKD | -328.91% |
| 2011 Q4 | -56.73 Million HKD | 0.0% |
| 2011 Q3 | -56.73 Million HKD | -328.91% |
| 2011 Q2 | 24.78 Million HKD | 0.0% |
| 2010 Q4 | 24.78 Million HKD | 0.0% |
| 2010 FY | 99.13 Million HKD | 116.46% |
| 2010 Q1 | 11.44 Million HKD | 0.0% |
| 2010 Q2 | 11.44 Million HKD | 0.0% |
| 2010 Q3 | 24.78 Million HKD | 116.46% |
| 2009 Q1 | -86.47 Million HKD | 0.0% |
| 2009 Q2 | -86.47 Million HKD | 0.0% |
| 2009 Q3 | 11.44 Million HKD | 113.24% |
| 2009 FY | 45.79 Million HKD | 113.24% |
| 2009 Q4 | 11.44 Million HKD | 0.0% |
| 2008 Q2 | 20.84 Million HKD | 0.0% |
| 2008 Q4 | -86.47 Million HKD | 0.0% |
| 2008 Q3 | -86.47 Million HKD | -514.84% |
| 2008 Q1 | 20.84 Million HKD | 0.0% |
| 2008 FY | -345.9 Million HKD | -514.84% |
| 2007 Q2 | 2.48 Million HKD | 0.0% |
| 2007 Q1 | 2.48 Million HKD | 0.0% |
| 2007 FY | 83.38 Million HKD | 740.29% |
| 2007 Q4 | 20.84 Million HKD | 0.0% |
| 2007 Q3 | 20.84 Million HKD | 740.29% |
| 2006 Q3 | 2.48 Million HKD | 109.35% |
| 2006 Q2 | -26.53 Million HKD | 0.0% |
| 2006 Q1 | -26.53 Million HKD | 0.0% |
| 2006 FY | 9.92 Million HKD | 109.35% |
| 2006 Q4 | 2.48 Million HKD | 0.0% |
| 2005 Q3 | -26.53 Million HKD | -57.9% |
| 2005 FY | -106.15 Million HKD | -57.9% |
| 2005 Q1 | -16.8 Million HKD | 0.0% |
| 2005 Q2 | -16.8 Million HKD | 0.0% |
| 2005 Q4 | -26.53 Million HKD | 0.0% |
| 2004 Q4 | -16.8 Million HKD | 0.0% |
| 2004 Q1 | -7.49 Million HKD | 0.0% |
| 2004 FY | -67.22 Million HKD | -124.19% |
| 2004 Q3 | -16.8 Million HKD | -124.19% |
| 2004 Q2 | -7.49 Million HKD | 0.0% |
| 2003 Q3 | -7.49 Million HKD | 0.0% |
| 2003 FY | -29.98 Million HKD | 0.0% |
| 2003 Q4 | -7.49 Million HKD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 105.03 Million HKD | 114.619% |
| Grand Pharmaceutical Group Limited | 1.87 Billion HKD | 100.817% |
| Extrawell Pharmaceutical Holdings Limited | -162.94 Million HKD | 90.576% |
| Qianhai Health Holdings Limited | -52.7 Million HKD | 70.864% |
| Lee's Pharmaceutical Holdings Limited | 16.69 Million HKD | 191.963% |
| Essex Bio-Technology Limited | 275.25 Million HKD | 105.579% |
| Tongfang Kontafarma Holdings Limited | -28.84 Million HKD | 46.76% |
| PuraPharm Corporation Limited | -106.08 Million HKD | 85.524% |
| SSY Group Limited | 1.31 Billion HKD | 101.165% |
| JBM (Healthcare) Limited | 130.46 Million HKD | 111.77% |
| Jacobson Pharma Corporation Limited | 266.96 Million HKD | 105.752% |
| China Resources Pharmaceutical Group Limited | 3.85 Billion HKD | 100.398% |